JONES BENJAMIN,FEHER VICTORIA,SMITH CHRISTOPHER,NIE ZHE,TAKAHASHI MASASHI,LAM BETTY,ARIKAWA YASUYOSHI,DONG QING
申请号：
NZ60126710
公开号：
NZ601267A
申请日:
2010.12.17
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
601267 Disclosed are pyrrolidinone compounds of formula (I) where the substituents are as disclosed in the specification. Examples of compounds of formal (I) are: 2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-chlorophenylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one 4-(1H-Indazol-6-ylamino)-2-((1R,2S)-2-aminocyclohexylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one 2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-dihydro-5H pyrrolo[3,4-d]pyrimidin-5-one. Also disclosed are pharmaceutical compositions or a combination product comprising a compound of formula (I) and the use of compounds of formula (I) in the manufacture of a medicament for the treatment of a diseases or condition for which SYK inhibitor is indicated. The diseases or condition may be selected from allergic rhinitis, allergic asthma, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, immune thrombocytopenic purpura, inflammatory bowel disease, chronic obstructive pulmonary disease, and thrombosis.
